Do Not Administer Albumin for Intradialytic Hypotension in This Patient with Normal Serum Albumin
Albumin should not be given to your ESRD patient experiencing intradialytic hypotension when serum albumin is in the normal range. The 2024 International Collaboration for Transfusion Medicine Guidelines explicitly recommend against routine albumin use for intradialytic hypotension, and this recommendation applies regardless of serum albumin levels 1.
Why Albumin Is Not Indicated
The evidence is clear and consistent:
No superiority over saline: A Cochrane systematic review found that 5% albumin showed no difference compared to normal saline in achieving target ultrafiltration or improving clinical outcomes in dialysis patients with intradialytic hypotension 1, 2. A well-designed double-blind RCT in 45 patients confirmed albumin offered no advantage over saline for treating intradialytic hypotension 3.
Cost without benefit: Albumin costs approximately $20,000 per patient annually when given three times weekly with maintenance hemodialysis, with no evidence supporting superiority over less costly alternatives 1.
Normal albumin negates theoretical benefit: The only recent trial (2021) showing potential benefit was specifically in hypoalbuminemic patients (albumin <3.0 g/dL), where 25% albumin improved hypotension rates and ultrafiltration 4. Your patient has normal albumin, placing them outside this narrow indication.
What You Should Do Instead
Prioritize these evidence-based interventions 1, 5:
Dialysis Prescription Modifications
- Increase dialysate calcium concentration (within safe limits)
- Lower dialysate temperature to 35-36°C
- Reduce ultrafiltration rate by extending treatment time
- Reassess target weight - may be set too low
Pharmacologic Options
- Midodrine (oral vasoconressor) - most widely used, though efficacy data are limited
- Consider timing of antihypertensive medications relative to dialysis
- Avoid highly dialyzable antihypertensives if intradialytic hypotension is frequent
Acute Management During Hypotensive Episodes
- Use normal saline (not albumin) for volume expansion 3, 2
- Trendelenburg positioning
- Reduce or temporarily stop ultrafiltration
Critical Caveats
The FDA label lists "Renal Dialysis" as a potential indication 6, stating albumin "may be of value in the treatment of shock or hypotension" in dialysis patients. However, this represents outdated labeling that predates high-quality evidence. The 2024 ICTMG guidelines explicitly reviewed this indication and found insufficient evidence to support routine use 1.
One important exception: If your patient were severely hypoalbuminemic (albumin <3.0 g/dL), the 2021 trial suggests 25% albumin might provide benefit 4. But with normal albumin levels, this does not apply.
The Bottom Line
Use normal saline for acute hypotensive episodes and focus on optimizing the dialysis prescription (dialysate temperature, calcium concentration, ultrafiltration rate) rather than albumin administration 1, 5. The guideline panel reviewed all available evidence and concluded albumin should not be used routinely for intradialytic hypotension, with very low certainty of evidence supporting its use 1.